Home
Live Updates
Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer : comparemela.com
Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.
Related Keywords
Joaquim Bellmunt ,
Genitourinary Oncology Program ,
Guidelines Committee ,
Bladder Cancer Center ,
Dana Farber Cancer Institute ,
Harvard Medical School ,
Patients With Metastatic Urothelial Cancer ,
Enfortumab Vedotin ,
Nivolumab ,
Pembrolizumab ,
Cisplatin Based Chemotherapy ,
Ev 302 ,
Checkmate 901 ,
comparemela.com © 2020. All Rights Reserved.